Compare Stocks: LYEL, ALMS, RIGL, and GLUE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$7.16 +2.7%	$15.74	$4.28 ▼ $31.35	$926.76M	-0.38	2.27 million shs	1.37 million shs
GLUE Monte Rosa Therapeutics	$10.30 -0.2%	$13.67	$8.52 ▼ $25.77	$878.69M	1.37	1.36 million shs	1.20 million shs
LYEL Lyell Immunopharma	$8.71 -0.9%	$12.61	$8.21 ▼ $45.00	$213.40M	-0.03	130,642 shs	106,807 shs
RIGL Rigel Pharmaceuticals	$49.08 +0.7%	$45.47	$24.95 ▼ $52.24	$908.08M	1.19	353,873 shs	279,362 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	+2.95%	-3.33%	-34.12%	-75.38%	+57.34%
GLUE Monte Rosa Therapeutics	+1.47%	-8.35%	-27.68%	-55.21%	+33.85%
LYEL Lyell Immunopharma	+2.69%	-6.59%	-35.03%	-41.44%	-51.86%
RIGL Rigel Pharmaceuticals	+1.52%	+3.73%	+2.85%	+14.50%	+69.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$7.16 +2.7%	$15.74	$4.28 ▼ $31.35	$926.76M	-0.38	2.27 million shs	1.37 million shs
GLUE Monte Rosa Therapeutics	$10.30 -0.2%	$13.67	$8.52 ▼ $25.77	$878.69M	1.37	1.36 million shs	1.20 million shs
LYEL Lyell Immunopharma	$8.71 -0.9%	$12.61	$8.21 ▼ $45.00	$213.40M	-0.03	130,642 shs	106,807 shs
RIGL Rigel Pharmaceuticals	$49.08 +0.7%	$45.47	$24.95 ▼ $52.24	$908.08M	1.19	353,873 shs	279,362 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	+2.95%	-3.33%	-34.12%	-75.38%	+57.34%
GLUE Monte Rosa Therapeutics	+1.47%	-8.35%	-27.68%	-55.21%	+33.85%
LYEL Lyell Immunopharma	+2.69%	-6.59%	-35.03%	-41.44%	-51.86%
RIGL Rigel Pharmaceuticals	+1.52%	+3.73%	+2.85%	+14.50%	+69.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.86	Moderate Buy	$33.27	364.70% Upside
GLUE Monte Rosa Therapeutics	2.82	Moderate Buy	$27.63	168.20% Upside
LYEL Lyell Immunopharma	2.78	Moderate Buy	$40.86	369.08% Upside
RIGL Rigel Pharmaceuticals	2.57	Moderate Buy	$59.00	20.21% Upside

Current Analyst Ratings Breakdown

Latest LYEL, ALMS, RIGL, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	ALMS Alumis	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/5/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/5/2026	GLUE Monte Rosa Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
10/5/2026	GLUE Monte Rosa Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/2/2026	ALMS Alumis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/1/2026	GLUE Monte Rosa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$25.00
10/1/2026	GLUE Monte Rosa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$25.00
9/16/2026	ALMS Alumis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/11/2026	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	LYEL Lyell Immunopharma	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
9/9/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$7.40M	125.27	N/A	N/A	$2.88 per share	2.49
GLUE Monte Rosa Therapeutics	$123.67M	7.11	N/A	N/A	$3.58 per share	2.88
LYEL Lyell Immunopharma	$40K	5,334.88	N/A	N/A	$11.68 per share	0.75
RIGL Rigel Pharmaceuticals	$276.79M	3.28	$6.89 per share	7.12	$21.57 per share	2.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-93.15%	-74.50%	11/12/2026 (Estimated)
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
LYEL Lyell Immunopharma	-$274.45M	-$12.83	N/A	N/A	N/A	-920,285.25%	-91.62%	-70.50%	11/10/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	3.01	11.36	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)

Latest LYEL, ALMS, RIGL, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	GLUE Monte Rosa Therapeutics	-$0.2396	N/A	N/A	N/A	$31.48 million	N/A
11/3/2026	Q3 2026	RIGL Rigel Pharmaceuticals	$0.9210	N/A	N/A	N/A	$80.10 million	N/A
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million
8/6/2026	Q2 2026	LYEL Lyell Immunopharma	-$1.94	-$1.9180	+$0.0220	-$1.92	$0.00 million	$0.00 million
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	6.74	6.74
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
LYEL Lyell Immunopharma	N/A	5.36	5.36
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
GLUE Monte Rosa Therapeutics	79.96%
LYEL Lyell Immunopharma	66.05%
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
GLUE Monte Rosa Therapeutics	6.40%
LYEL Lyell Immunopharma	6.20%
RIGL Rigel Pharmaceuticals	10.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	239	129.44 million	85.82 million	N/A
GLUE Monte Rosa Therapeutics	173	85.31 million	79.85 million	Optionable
LYEL Lyell Immunopharma	161	24.50 million	22.99 million	Optionable
RIGL Rigel Pharmaceuticals	174	18.50 million	16.57 million	Optionable

LYEL, ALMS, RIGL, and GLUE Headlines

Recent News About These Companies

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 2, 2026 | prnewswire.com

Contrasting Regeneron Pharmaceuticals (NASDAQ:REGN) and Rigel Pharmaceuticals (NASDAQ:RIGL)

October 2, 2026 | americanbankingnews.com

RIGL.OQ - | Stock Price & Latest News | Reuters

October 1, 2026 | reuters.com

Bank of America Corp DE Purchases 123,506 Shares of Rigel Pharmaceuticals, Inc. $RIGL

September 29, 2026 | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up - Here's What Happened

September 23, 2026 | marketbeat.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Moderate Buy" from Brokerages

September 20, 2026 | marketbeat.com

Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

September 15, 2026 | seekingalpha.com

Rigel Pharmaceuticals op H.C. Wainwright-conferentie: groeiplan verbreed

September 15, 2026 | nl.investing.com

Rigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow

September 15, 2026 | seekingalpha.com

Squarepoint Ops LLC Acquires 38,550 Shares of Rigel Pharmaceuticals, Inc. $RIGL

September 14, 2026 | marketbeat.com

Rigel to Participate in Upcoming September Investor Conferences

September 2, 2026 | prnewswire.com

Rigel Pharmaceuticals

August 17, 2026 | money.usnews.com

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

August 13, 2026 | prnewswire.com

Rigel Pharmaceuticals en quête d'acquisitions

August 5, 2026 | zonebourse.comZ

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

August 5, 2026 | seekingalpha.com

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

August 5, 2026 | seekingalpha.com

Rigel: Q2 Earnings Snapshot

August 4, 2026 | aol.comA

Rigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 4, 2026 | seekingalpha.com

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

August 4, 2026 | seekingalpha.com

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

August 4, 2026 | zacks.com

Rigel Reports Second Quarter 2026 Financial Results

August 4, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, ALMS, RIGL, and GLUE Company Descriptions

Alumis NASDAQ:ALMS

$7.16 +0.19 (+2.73%)

Closing price 04:00 PM Eastern

Extended Trading

$7.09 -0.07 (-0.98%)

As of 05:46 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Monte Rosa Therapeutics NASDAQ:GLUE

$10.30 -0.02 (-0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$10.38 +0.08 (+0.77%)

As of 06:09 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Lyell Immunopharma NASDAQ:LYEL

$8.71 -0.08 (-0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$8.70 -0.01 (-0.06%)

As of 04:10 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Rigel Pharmaceuticals NASDAQ:RIGL

$49.08 +0.36 (+0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$49.18 +0.11 (+0.21%)

As of 04:38 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LYEL, ALMS, RIGL, and GLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LYEL, ALMS, RIGL, and GLUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LYEL, ALMS, RIGL, and GLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, ALMS, RIGL, and GLUE Company Descriptions

Alumis NASDAQ:ALMS

Monte Rosa Therapeutics NASDAQ:GLUE

Lyell Immunopharma NASDAQ:LYEL

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LYEL, ALMS, RIGL, and GLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LYEL, ALMS, RIGL, and GLUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LYEL, ALMS, RIGL, and GLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, ALMS, RIGL, and GLUE Company Descriptions

Alumis NASDAQ:ALMS

Monte Rosa Therapeutics NASDAQ:GLUE

Lyell Immunopharma NASDAQ:LYEL

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools